CD147
- Known as:
- CD147
- Catalog number:
- 11-274-C100
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD147
Related genes to: CD147
- Gene:
- BSG NIH gene
- Name:
- basigin (Ok blood group)
- Previous symbol:
- OK
- Synonyms:
- EMMPRIN, CD147, EMPRIN
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-25
- Date modifiied:
- 2019-04-23
Related products to: CD147
Related articles to: CD147
- Smoking cessation decreases lung cancer progression; however, its effects on precancerous lesions and the underlying mechanisms remain unclear. This study established a mouse model of precancerous pulmonary nodules and employed single-cell RNA sequencing (scRNA-seq) and immune repertoire sequencing (IR-seq) to elucidate the regulatory mechanisms by which smoking cessation influences the development of lung precancerous lesions. - Source: PubMed
Publication date: 2026/08/13
Wang XintongTang FangQin JiayuXiao TiquanShi LiweiZhang ShujunChe Chunli - Irritable bowel syndrome with diarrhoea (IBS-D) is one of the most frequently encountered disorders of gut-brain interaction, yet its diagnosis remains challenging owing to the substantial symptom overlap with a wide range of conditions. These mimics, most notably microscopic colitis (MC), bile acid diarrhoea (BAD), small intestinal bacterial overgrowth (SIBO), coeliac disease, exocrine pancreatic insufficiency (EPI), endocrine disorders, lactase deficiency, sucrase-isomaltase deficiency, early inflammatory bowel disease (IBD) and functional diarrhoea (FD) can all present with identical clinical features, leading to diagnostic error, delayed treatment, and inappropriate symptom-based management. This narrative review synthesizes literature from 1997 to 2025, incorporating guideline recommendations (ACG, AGA, BSG, ECCO), RCTs, meta-analyses, systematic reviews, and expert consensus statements. This review highlights the most critical mistakes in diagnosing, evaluating, managing, and monitoring IBS-D and its mimics, with lapses in clinical reasoning and guideline adherence most consequential. - Source: PubMed
Publication date: 2026/08/13
Senadheera PavithraSilva BhagyaJayasena HiruniNiriella Madunil - Acral melanoma (AM) exhibits significant intratumoral heterogeneity, but its tumor microenvironment (TME) and immune regulation remain unclear. This study aims to dissect TME heterogeneity and establish a prognostic model based on key cell subpopulations. - Source: PubMed
Publication date: 2026/08/06
Jing MingXu ZhenRuan ZhenqiangZhao XiangrongYang JiguangZhang QiMao KeleiGao ChaoYan Xiaodong - The progression of carotid plaques is closely associated with immune dysregulation. This study aimed to identify key natural killer (NK) cell-related genes and to explore their immune microenvironment using bulk and single-cell transcriptomic data. - Source: PubMed
Publication date: 2026/08/03
Shen LunLiu YangXue JingnanQi LuyingWang JiachenZhang YanSha WenliBao Yunfei - Cholangiocarcinoma (CCA) is a highly aggressive, molecularly heterogeneous biliary tract malignancy and the second most common primary liver cancer, and it has an increasing global incidence and persistently poor prognosis. Recent updates of international guidelines, including those from the NCCN, ESMO, EASL, CSCO, BSG, and Japanese societies, along with rapid advances in precision oncology, have substantially changed the clinical management of CCA. This review systematically compares current global guidelines, highlighting both areas of consensus and regional differences in epidemiology, risk factors, screening strategies, diagnostic approaches, pathological and molecular classification, staging systems, surgical indications, systemic therapy, and multidisciplinary management. This review also summarizes recent advances in molecular diagnostics, including next-generation sequencing, liquid biopsy, circulating tumor DNA, extracellular vesicles, artificial intelligence-assisted imaging, radiomics, and emerging prognostic biomarkers. The evolving roles of immune checkpoint inhibitors, molecularly targeted therapies against FGFR2, IDH1, HER2, BRAF, NTRK, and MSI-H/dMMR, liver transplantation, locoregional treatment, and conversion (translational) therapy are also discussed. Finally, this review addresses current challenges, including drug resistance, limited access to molecular testing, regional disparities in healthcare resources, and the lack of universally accepted screening strategies. By integrating updated guideline recommendations with the latest clinical evidence, this review provides a comprehensive reference for evidence-based clinical decision-making and future translational research in CCA. - Source: PubMed
Publication date: 2026/07/31
He EnyangCai YulongXiong XianzeZhou RongxingLi FuyuCheng Nansheng